Detalhe da pesquisa
1.
Inflammation and vascular diseases.
Vnitr Lek
; 68(5): 309-314, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36283822
2.
Are proton pump inhibitors an effective and safe drug not only in the prophylaxis of gastrointestinal bleeding in antithrombotic treatment?
Vnitr Lek
; 66(3): 169-179, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32972161
3.
Diosmin/hesperidin: a cooperating tandem, or is diosmin crucial and hesperidin an inactive ingredient only?
Vnitr Lek
; 66(2): 97-103, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32942884
4.
Anticoagulant therapy in the elderly.
Vnitr Lek
; 64(11): 1011-1020, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30606017
5.
[Mountain sickness]. / Výsková nemoc.
Cas Lek Cesk
; 154(6): 280-6, 2015.
Artigo
em Tcheco
| MEDLINE | ID: mdl-26750624
6.
[Anticoagulant therapy in secondary prevention of coronary events]. / Antikoagulacní lécba v sekundární prevenci koronárních príhod.
Vnitr Lek
; 60(12): 1023-32, 2014 Dec.
Artigo
em Tcheco
| MEDLINE | ID: mdl-25692828
7.
[Extended options of anticoagulant treatment in thromboembolism]. / Rozsirující se moznosti antikoagulacní lécby tromboembolické nemoci.
Vnitr Lek
; 60(11): 977-84, 2014 Nov.
Artigo
em Tcheco
| MEDLINE | ID: mdl-25600045
8.
Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?
Eur Heart J
; 31(21): 2650-9, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20494902
9.
[Pharmacogenetics in cardiovascular diseases therapy--treatment according guidelines or according the individual requirement?]. / Farmakogenetika v lécbe kardiovaskulárních chorob aneb lécba podle guidelines ci podle potreb nemocného?
Cas Lek Cesk
; 149(10): 476-81, 2010.
Artigo
em Tcheco
| MEDLINE | ID: mdl-21121138
10.
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.
Nephrol Dial Transplant
; 24(7): 2102-11, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19218538
11.
Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.
Ann Intern Med
; 146(2): 77-86, 2007 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-17179052
12.
The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease.
Genet Med
; 9(8): 504-9, 2007 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17700388
13.
Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition.
Arterioscler Thromb Vasc Biol
; 26(4): 839-44, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16469946
14.
Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population.
J Mol Med (Berl)
; 83(8): 647-54, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15806320
15.
Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease.
Acta Paediatr Suppl
; 95(451): 63-8, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16720468
16.
Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial.
J Am Coll Cardiol
; 40(5): 917-25, 2002 Sep 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-12225716
17.
Association between tyrosine hydroxylase polymorphisms and left ventricular structure in young normotensive men.
Br J Biomed Sci
; 59(2): 90-4, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12113410
18.
Association between cardiac energy metabolism and gain of left ventricular mass in Fabry disease.
Int J Cardiol
; 144(2): 337-9, 2010 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-19344961
19.
Right ventricular involvement in Fabry disease.
J Am Soc Echocardiogr
; 21(11): 1265-8, 2008 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-18835697
20.
Onset and progression of the Anderson-Fabry disease related cardiomyopathy.
Int J Cardiol
; 130(3): 367-73, 2008 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-18572264